Imuran

Azathioprine, the active ingredient in Imuran, is an immunosuppressant (antimetabolite) presented as an oral tablet for oral use. It is employed to reduce immune activity in patients undergoing organ transplantation, as well as in chronic inflammatory conditions such as rheumatoid arthritis and inflammatory bowel disease. GNH USA supplies Imuran as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres and pharmacies worldwide.

Imuran is an immunosuppressive agent used in several autoimmune and transplant‑related disease pathways. - Organ transplantation prophylaxis: helps prevent rejection by suppressing T‑cell activation. - Rheumatoid arthritis: reduces joint inflammation and slows disease progression in moderate to severe cases. - Inflammatory bowel disease (Crohn's disease, ulcerative colitis): diminishes intestinal inflammation and maintains remission in patients unresponsive to first‑line therapies.

Adverse reactions to Imuran vary in frequency and severity.

Common Side Effects: - Nausea or vomiting: gastrointestinal discomfort occurring shortly after dosing. - Decreased white blood cell count: mild leukopenia that may increase infection risk. - Elevated liver enzymes: transient hepatic enzyme changes detectable on routine labs. - Fatigue or malaise: general feeling of tiredness without specific cause.

Serious or Rare Side Effects: - Severe bone marrow suppression: pancytopenia requiring immediate medical attention. - Hepatotoxicity: significant liver injury presenting with jaundice or abnormal labs. - Increased risk of opportunistic infections: due to profound immunosuppression.

Imuran requires careful monitoring and patient education before initiation. - Baseline testing: obtain complete blood count and liver function tests prior to therapy. - Regular monitoring: schedule periodic CBC and hepatic panels to detect toxicity early. - Infection vigilance: advise patients to report fever, sore throat, or unexplained infections promptly. - Drug interactions: review concomitant medications for potential synergistic myelosuppression. - Store at ambient temperature: keep tablets below 25 °C in the original container, protected from moisture and direct sunlight.

Imuran may interact with several medicines, altering efficacy or safety.

Major Interactions (Avoid): - Allopurinol or febuxostat: can markedly increase azathioprine toxicity; concurrent use is contraindicated. - Mycophenolate mofetil: combined immunosuppression may cause severe bone marrow suppression.

Moderate Interactions (Monitor Closely): - Warfarin: azathioprine may enhance anticoagulant effect; monitor INR closely. - Ribavirin: potential additive hematologic toxicity; regular blood counts recommended. - Live vaccines: immunosuppression may reduce vaccine efficacy and increase infection risk; avoid administration while on therapy.